Hori­zon touts PhIV win for Te­pez­za; FDA sets ad­comm dates for Sarep­ta, Pfiz­er, Ei­sai apps

Hori­zon Ther­a­peu­tics’ Te­pez­za, which treats a rare au­toim­mune dis­ease that af­fects the eye, has cleared a Phase IV tri­al de­signed to il­lus­trate the drug’s use in a spe­cif­ic pa­tient pop­u­la­tion with chron­ic thy­roid eye dis­ease.

The biotech — which is set to be­come part of Am­gen once its $28.3 bil­lion deal goes through — tar­get­ed thy­roid eye dis­ease pa­tients with low clin­i­cal ac­tiv­i­ty scores for the tri­al. The pri­ma­ry end­point was mea­sured by prop­to­sis or the bulging of one or both eyes from the nat­ur­al po­si­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.